BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS
- Organic revenue remained flat at $272.6 million
- Cash flow from operations increased to $142.5 million, an 18% increase from the prior year
- 20% growth in instrument consumables
- Appointment of Matthew F. McManus to President of the Diagnostics and Genomics segment
- Encouraging signs of stabilization in China
- Unique life science tools and diagnostics portfolio
- Financial strength and deep scientific capabilities
- 2% organic revenue decline
- GAAP EPS decreased to $0.17 per diluted share
- GAAP operating income decreased 44% to $38.0 million
- Adjusted EPS decreased to $0.40 per diluted share
- Adjusted operating income decreased 15%
- Protein Sciences segment's net sales decreased 3%
- Protein Sciences segment's operating margin decreased to 40.3%
- Diagnostics and Genomics segment's operating margin decreased to 6.0%
Insights
An examination of Bio-Techne Corporation's Q2 FY2024 financial results indicates a mixed financial performance, with several factors influencing the company's earnings and revenue. A notable decline in organic revenue by 2% and a decrease in GAAP EPS from $0.31 to $0.17 suggest a contraction in profitability compared to the previous year. Adjusted EPS also saw a reduction from $0.47 to $0.40, reflecting challenges in operational efficiency and cost management. However, the 18% increase in cash flow from operations is a positive sign, showing improved liquidity which could support future investments and debt management.
The impact of macroeconomic conditions on the BioPharma industry and the acquisition of Lunaphore have been highlighted as significant factors affecting the financial outcomes. The decline in GAAP operating income by 44% and the decrease in operating margins for both the Protein Sciences and Diagnostics and Genomics segments indicate pressure on the company's profitability. These changes in operating margins could be attributed to unfavorable volume and product mix, as well as acquisition-related expenses.
Investors may view the growth in the academic end market and signs of stabilization in China as potential opportunities for recovery and future growth. The long-term outlook may be bolstered by the company's strategic positioning in life science tools and diagnostics, as well as their financial strength and scientific capabilities. However, the short-term challenges reflected in the financials could affect investor confidence and stock performance.
The reported 20% growth in instrument consumables within Bio-Techne's portfolio suggests a strong demand for the company's products, particularly in the academic end market. This is indicative of the company's ability to maintain relevance and competitiveness in a segment that appears to be resilient amid broader industry challenges. The strategic appointment of Matthew F. McManus to President of the Diagnostics and Genomics segment could be a move to strengthen the company's leadership in a key growth area, potentially driving innovation and market expansion.
Despite the decline in organic revenue and adjusted earnings, the company's emphasis on providing highly productive analytical tools and its focus on the academic market could present avenues for recovery and growth. The mention of initial signs of stabilization in China is particularly significant given the size and growth potential of the Chinese market for life science and diagnostics products. The ability to navigate the 'challenging China landscape' will be crucial for Bio-Techne's long-term success in the region.
The financial report from Bio-Techne provides insights into the company's performance within the context of the biotechnology and diagnostics industry. The decline in organic revenue in the Protein Sciences segment, which supplies proteins, antibodies and reagents to the research community, may reflect broader trends in research funding and priorities. However, the growth in the Diagnostics and Genomics segment aligns with the increasing importance of personalized medicine and the demand for diagnostic solutions, including spatial biology products and exosome-based diagnostics.
Understanding the financial health of Bio-Techne is essential for stakeholders who are interested in the company's ability to sustain innovation and growth in the biotech and diagnostic fields. The financial pressures observed in the report could potentially affect the company's R&D investments and its ability to bring new products to market, which are critical for maintaining a competitive edge in these sectors.
Second Quarter FY2024 Highlights
- Second quarter organic revenue declined by
2% (0% reported) to$272.6 million 2% reported) in the first half of fiscal 2024 at$549.5 million - GAAP earnings per share (EPS) was
$0.17 $0.31 $0.40 $0.47 - The impact of the BioPharma macroeconomic conditions that the industry has experienced throughout the past calendar year increased in our fiscal second quarter. The company has been able to partially offset this headwind by providing our customers highly productive analytical tools, which is demonstrated by
20% growth in our instrument consumables. - Strong commercial execution in the academic end market with high single-digit growth.
- Cash flow generated from operations increased to
$142.5 million 18% increase from the prior year. - Appointment of Matthew F. McManus to President of the Diagnostics and Genomics segment.
The Company's financial statements are prepared in accordance with accounting principles generally accepted in
"I am pleased with the team's continued execution in this dynamic operating environment, as we navigated a challenging
Kelderman added, "Our unique life science tools and diagnostics portfolio, financial strength, experienced team, and deep scientific capabilities position Bio-Techne to create value for all of our stakeholders going forward."
Kelderman concluded, "Lastly, I want to thank Chuck Kummeth for his support in my transition, prior to his retirement from Bio-Techne on July 1, 2024. Chuck did a remarkable job growing Bio-Techne during his 11-year tenure as CEO. I am excited to lead this talented team through the next phase of growth."
Bio-Techne will host an earnings conference call today, February 1, 2024 at 8:00 a.m. CST. To listen, please dial 1-877-407-9208 or 1-201-493-6784 for international callers, and reference conference ID 13743935. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13743935. The replay will be available from 11:00 a.m. CST on Thursday, February 1, 2024, until 11:00 p.m. CST on Friday, March 1, 2024.
Second Quarter Fiscal 2024
Revenue
Net sales for the second quarter remained flat at
GAAP Earnings Results
GAAP EPS was
Non-GAAP Earnings Results
Adjusted EPS decreased to
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.
Protein Sciences Segment
The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment's second quarter fiscal 2024 net sales were
Diagnostics and Genomics Segment
The Company's Diagnostics and Genomics segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Genomics segment also develops and provides spatial biology products as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Genomics segment's second quarter fiscal 2024 net sales were
Use of non-GAAP Adjusted Financial Measures:
This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the
- Organic revenue
- Adjusted diluted earnings per share
- Adjusted net earnings
- Adjusted tax rate
- Adjusted gross margin
- Adjusted operating income
- Adjusted operating margin
- Earnings before interest, taxes, depreciation, and amortization (EBITDA)
- Adjusted EBITDA
We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.
Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal year 2024 due to the sale of Changzhou Eminence Biotechnology Co., Ltd. (Eminence) in the first quarter of fiscal 2023. Revenue from partially-owned consolidated subsidiaries was
Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs, and other non-recurring items including non-recurring costs, goodwill and long-lived asset impairments, and gains. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on legal settlements, goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries in the calculation of our non-GAAP financial measures as the revenues and expenses are not fully attributable to the Company.
The Company's non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.
Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues resulting from the COVID-19 pandemic, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
612-656-4416 |
BIO-TECHNE CORPORATION | ||||||||||||
CONSOLIDATED STATEMENTS OF EARNINGS | ||||||||||||
(In thousands, except per share data) | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | SIX MONTHS | |||||||||||
ENDED | ENDED | |||||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | |||||||||
Net Sales | $ | 272,598 | $ | 271,581 | $ | 549,533 | $ | 541,236 | ||||
Cost of sales | 96,011 | 88,221 | 187,755 | 178,280 | ||||||||
Gross margin | 176,587 | 183,360 | 361,778 | 362,956 | ||||||||
Operating Expenses: | ||||||||||||
Selling, general and administrative | 115,667 | 93,010 | 220,998 | 192,386 | ||||||||
Research and development | 22,916 | 22,459 | 46,914 | 46,362 | ||||||||
Total Operating Expenses | 138,583 | 115,469 | 267,912 | 238,748 | ||||||||
Operating income | 38,004 | 67,891 | 93,866 | 124,208 | ||||||||
Other income (expense) | (4,617) | (1,462) | (10,921) | 45,938 | ||||||||
Earnings before income taxes | 33,387 | 66,429 | 82,945 | 170,146 | ||||||||
Income taxes (benefit) | 5,922 | 16,424 | 4,486 | 30,407 | ||||||||
Net earnings, including noncontrolling interest | $ | 27,465 | $ | 50,005 | $ | 78,459 | $ | 139,739 | ||||
Net earnings attributable to noncontrolling interest | — | — | — | 179 | ||||||||
Net earnings attributable to Bio-Techne | $ | 27,465 | $ | 50,005 | $ | 78,459 | $ | 139,560 | ||||
Earnings per share: | ||||||||||||
Basic | $ | 0.17 | $ | 0.32 | $ | 0.50 | $ | 0.89 | ||||
Diluted | $ | 0.17 | $ | 0.31 | $ | 0.49 | $ | 0.86 | ||||
Weighted average common shares outstanding | ||||||||||||
Basic | 157,533 | 157,011 | 157,826 | 156,887 | ||||||||
Diluted | 160,060 | 161,750 | 161,001 | 161,766 | ||||||||
BIO-TECHNE CORPORATION | ||||||
CONSOLIDATED CONDENSED BALANCE SHEETS | ||||||
(In thousands) | ||||||
(Unaudited) | ||||||
12/31/2023 | 6/30/2023 | |||||
ASSETS | ||||||
Cash and equivalents | $ | 130,132 | $ | 180,571 | ||
Short-term available-for-sale investments | 5,520 | 23,739 | ||||
Accounts receivable, net | 207,451 | 218,468 | ||||
Inventories | 180,839 | 171,638 | ||||
Current assets held-for-sale | 26,647 | — | ||||
Other current assets | 40,051 | 27,066 | ||||
Total current assets | 590,640 | 621,482 | ||||
Property and equipment, net | 234,204 | 226,200 | ||||
Right of use asset | 100,863 | 98,326 | ||||
Goodwill and intangible assets, net | 1,530,687 | 1,407,382 | ||||
Other assets | 274,359 | 285,302 | ||||
Total assets | $ | 2,730,753 | $ | 2,638,692 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Accounts payable and accrued expenses | $ | 81,668 | $ | 77,306 | ||
Contract liabilities | 28,427 | 23,069 | ||||
Income taxes payable | 6,646 | 12,022 | ||||
Contingent consideration payable | — | 3,500 | ||||
Operating lease liabilities - current | 12,672 | 11,199 | ||||
Current liabilities held-for-sale | 1,593 | — | ||||
Other current liabilities | 4,225 | 1,413 | ||||
Total current liabilities | 135,231 | 128,509 | ||||
Deferred income taxes | 71,575 | 88,982 | ||||
Long-term debt obligations | 447,000 | 350,000 | ||||
Operating lease liabilities | 96,027 | 93,766 | ||||
Other long-term liabilities | 17,361 | 10,919 | ||||
Stockholders' equity | 1,963,559 | 1,966,516 | ||||
Total liabilities and stockholders' equity | $ | 2,730,753 | $ | 2,638,692 | ||
BIO-TECHNE CORPORATION | ||||||||||||
RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | SIX MONTHS | |||||||||||
ENDED | ENDED | |||||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | |||||||||
Gross margin percentage - GAAP | 64.8 | % | 67.5 | % | 65.8 | % | 67.1 | % | ||||
Identified adjustments: | ||||||||||||
Costs recognized upon sale of acquired inventory | 0.1 | % | 0.0 | % | 0.1 | % | 0.1 | % | ||||
Amortization of intangibles | 4.3 | % | 4.1 | % | 4.3 | % | 4.1 | % | ||||
Stock compensation expense | 0.1 | % | 0.1 | % | 0.1 | % | 0.1 | % | ||||
Restructuring and restructuring-related costs | 0.4 | % | — | % | 0.2 | % | — | % | ||||
Impact of partially-owned consolidated subsidiaries1) | — | % | — | % | — | % | (0.1) | % | ||||
Gross margin percentage - Adjusted | 69.7 | % | 71.7 | % | 70.5 | % | 71.3 | % | ||||
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. |
BIO-TECHNE CORPORATION | ||||||||||||
RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | SIX MONTHS | |||||||||||
ENDED | ENDED | |||||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | |||||||||
Operating margin percentage - GAAP | 13.9 | % | 25.0 | % | 17.1 | % | 22.9 | % | ||||
Identified adjustments: | ||||||||||||
Costs recognized upon sale of acquired inventory | 0.1 | % | 0.0 | % | 0.1 | % | 0.1 | % | ||||
Amortization of intangibles | 7.3 | % | 7.0 | % | 7.2 | % | 7.1 | % | ||||
Acquisition related expenses and other | (0.2) | % | (3.0) | % | (0.2) | % | (1.3) | % | ||||
Stock-based compensation, inclusive of employer taxes | 4.8 | % | 6.2 | % | 4.4 | % | 6.0 | % | ||||
Restructuring and restructuring-related costs | 2.0 | % | 0.3 | % | 1.0 | % | 0.5 | % | ||||
Impairment of assets held-for-sale | 2.2 | % | — | % | 1.1 | % | — | % | ||||
Impact of partially-owned consolidated subsidiaries1) | — | % | — | % | — | % | (0.1) | % | ||||
Operating margin percentage - Adjusted | 30.1 | % | 35.5 | % | 30.7 | % | 35.2 | % | ||||
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. As disclosed in our use of Non-GAAP Adjusted Financial Measures, the adjusted operating margin percentages excludes partially-owned consolidated revenue and expense amounts. Due to the sale of this partially-owned consolidated subsidiary in the first fiscal quarter of 2023, there was no impact on operating margin for quarter and six months ended December 31, 2023 and the quarter ended December 31, 2022. The excluded revenue and excluded operating (income)/loss attributable to partially-owned consolidated subsidiaries had a |
BIO-TECHNE CORPORATION | |||||||||||||
NON-GAAP ADJUSTED CONSOLIDATED NET EARNINGS and EARNINGS per SHARE | |||||||||||||
(In thousands, except per share data) (Unaudited) | |||||||||||||
QUARTER | SIX MONTHS | ||||||||||||
ENDED | ENDED | ||||||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | ||||||||||
Net earnings before taxes - GAAP | $ | 33,387 | $ | 66,429 | $ | 82,945 | $ | 170,146 | |||||
Identified adjustments attributable to Bio-Techne: | |||||||||||||
Costs recognized upon sale of acquired inventory | 183 | 100 | 364 | 400 | |||||||||
Amortization of intangibles | 19,769 | 19,125 | 39,620 | 38,408 | |||||||||
Amortization of Wilson Wolf intangible assets and acquired inventory | 4,208 | — | 8,416 | — | |||||||||
Acquisition related expenses and other | (381) | (8,162) | (822) | (7,484) | |||||||||
Gain on sale of partially-owned consolidated subsidiaries | — | — | — | (11,682) | |||||||||
Stock-based compensation, inclusive of employer taxes | 12,958 | 16,878 | 24,453 | 32,336 | |||||||||
Restructuring and restructuring-related costs | 5,518 | 780 | 5,607 | 2,950 | |||||||||
Investment (gain) loss and other non-operating | — | 74 | (283) | (38,013) | |||||||||
Impairment of assets held-for-sale | 6,038 | — | 6,038 | — | |||||||||
Impact of partially-owned consolidated subsidiaries1) | — | — | — | (420) | |||||||||
Net earnings before taxes - Adjusted1) | $ | 81,680 | $ | 95,224 | $ | 166,338 | $ | 186,641 | |||||
Non-GAAP tax rate | 22.0 | % | 21.0 | % | 22.0 | % | 21.0 | % | |||||
Non-GAAP tax expense | $ | 17,964 | $ | 19,998 | $ | 36,579 | $ | 39,195 | |||||
Non-GAAP adjusted net earnings attributable to Bio-Techne1) | $ | 63,716 | $ | 75,226 | $ | 129,759 | $ | 147,446 | |||||
Earnings per share - diluted - Adjusted1) | $ | 0.40 | $ | 0.47 | $ | 0.81 | $ | 0.91 | |||||
1) | Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. |
BIO-TECHNE CORPORATION | |||||||||||
NON-GAAP adjusted tax rate (In percentages) | |||||||||||
(Unaudited) | |||||||||||
QUARTER | SIX MONTHS | ||||||||||
ENDED | ENDED | ||||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | ||||||||
GAAP effective tax rate | 17.7 | % | 24.7 | % | 5.4 | % | 17.9 | % | |||
Discrete items | 8.3 | (7.0) | 18.0 | 1.9 | |||||||
Impact of non-taxable net gain | — | (0.2) | — | 1.4 | |||||||
Annual forecast update | (2.6) | 3.7 | — | — | |||||||
Long-term GAAP tax rate | 23.4 | % | 21.2 | % | 23.4 | % | 21.2 | % | |||
Rate impact items | |||||||||||
Stock based compensation | (2.1) | % | (2.0) | % | (2.4) | % | (2.5) | % | |||
Other | 0.7 | 1.8 | 1.0 | 2.3 | |||||||
Total rate impact items | (1.4) | % | (0.2) | % | (1.4) | % | (0.2) | % | |||
Non-GAAP adjusted tax rate | 22.0 | % | 21.0 | % | 22.0 | % | 21.0 | % | |||
BIO-TECHNE CORPORATION | ||||||||||||
SEGMENT REVENUE | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | SIX MONTHS | |||||||||||
ENDED | ENDED | |||||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | |||||||||
Protein Sciences segment revenue | $ | 197,670 | $ | 203,887 | $ | 402,325 | $ | 403,836 | ||||
Diagnostics and Genomics segment revenue | 75,408 | 68,003 | 148,204 | 137,907 | ||||||||
lntersegment revenue | (480) | (309) | (996) | (507) | ||||||||
Consolidated revenue | $ | 272,598 | $ | 271,581 | $ | 549,533 | $ | 541,236 | ||||
BIO-TECHNE CORPORATION | ||||||||||||
SEGMENT OPERATING INCOME | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
QUARTER | SIX MONTHS | |||||||||||
ENDED | ENDED | |||||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | |||||||||
Protein Sciences segment operating income | $ | 79,586 | $ | 89,336 | $ | 167,947 | $ | 175,278 | ||||
Diagnostics and Genomics segment operating income | 4,556 | 8,296 | 5,082 | 16,934 | ||||||||
Segment operating income | 84,142 | 97,632 | 173,029 | 192,212 | ||||||||
Corporate general, selling, and administrative | (2,197) | (1,165) | (4,195) | (2,567) | ||||||||
Adjusted operating income | 81,945 | 96,467 | 168,834 | 189,645 | ||||||||
Cost recognized upon sale of acquired inventory | (183) | (100) | (364) | (400) | ||||||||
Amortization of intangibles | (19,769) | (19,125) | (39,620) | (38,408) | ||||||||
Acquisition related expenses and other | 525 | 8,307 | 1,114 | 8,010 | ||||||||
Impact of partially-owned consolidated subsidiaries1) | — | — | — | 647 | ||||||||
Stock-based compensation, inclusive of employer taxes | (12,958) | (16,878) | (24,453) | (32,336) | ||||||||
Restructuring and restructuring-related costs | (5,518) | (780) | (5,607) | (2,950) | ||||||||
Impairment of assets held-for-sale | (6,038) | — | (6,038) | — | ||||||||
Operating income | $ | 38,004 | $ | 67,891 | $ | 93,866 | $ | 124,208 | ||||
1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. |
BIO-TECHNE CORPORATION | ||||||||||
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA | ||||||||||
(In thousands) | ||||||||||
(Unaudited) | ||||||||||
QUARTER | SIX MONTHS | |||||||||
ENDED | ENDED | |||||||||
12/31/2023 | 12/31/2022 | 12/31/2023 | 12/31/2022 | |||||||
Net earnings attributable to Bio-Techne | $ | 27,465 | $ | 50,005 | $ | 78,459 | $ | 139,560 | ||
Net interest expense (income) | 3,513 | 1,388 | 7,516 | 4,745 | ||||||
Depreciation and amortization | 27,804 | 26,703 | 56,343 | 53,344 | ||||||
Income taxes (benefit) | 5,922 | 16,424 | 4,486 | 30,407 | ||||||
EBITDA attributable to Bio-Techne | 64,704 | 94,520 | 146,804 | 228,056 | ||||||
Costs recognized upon sale of acquired inventory | 183 | 100 | 364 | 400 | ||||||
Acquisition related expenses and other | (381) | (8,162) | (822) | (7,484) | ||||||
Amortization of Wilson Wolf intangible assets and acquired inventory | 4,208 | — | 8,416 | — | ||||||
Gain on sale of partially-owned consolidated subsidiaries | — | — | — | (11,682) | ||||||
Stock-based compensation, inclusive of employer taxes | 12,958 | 16,878 | 24,453 | 32,336 | ||||||
Restructuring and restructuring-related costs | 5,518 | 780 | 5,607 | 2,950 | ||||||
Investment (gain) loss and other non-operating | — | 74 | (283) | (38,013) | ||||||
Impairment of assets held-for-sale | 6,038 | — | 6,038 | — | ||||||
Impact of partially-owned consolidated subsidiaries1) | — | — | — | (241) | ||||||
Adjusted EBITDA | $ | 93,228 | $ | 104,190 | $ | 190,577 | $ | 206,322 | ||
1) | Net earnings attributable to Bio-Techne excludes non-controlling interest of approximately |
BIO-TECHNE CORPORATION | ||||||
CONDENSED CASH FLOW | ||||||
(In thousands) | ||||||
(Unaudited) | ||||||
SIX MONTHS | ||||||
ENDED | ||||||
12/31/2023 | 12/31/2022 | |||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||
Net earnings | $ | 78,459 | $ | 139,739 | ||
Adjustments to reconcile net earnings to net cash provided by operating activities | ||||||
Depreciation and amortization | 56,343 | 53,344 | ||||
Costs recognized on sale of acquired inventory | 364 | 400 | ||||
Deferred income taxes | (22,314) | (6,365) | ||||
Stock-based compensation expense | 22,846 | 31,205 | ||||
Gain on sale of CCXI investment | — | (37,176) | ||||
Fair value adjustment to available-for-sale investments | (283) | (839) | ||||
(Gain) loss on equity method investment | 4,295 | — | ||||
Fair value adjustment to contingent consideration payable | (3,500) | (8,600) | ||||
Gain on sale of Eminence | — | (11,682) | ||||
Impairment of assets held-for-sale | 6,038 | — | ||||
Other operating activities | 251 | (39,561) | ||||
Net cash provided by (used in) operating activities | 142,499 | 120,465 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||
Proceeds from sale of available-for-sale investments | 23,759 | 26,509 | ||||
Purchases of available-for-sale investments | (5,526) | (20,500) | ||||
Proceeds from sale of CCXI investment | — | 73,219 | ||||
Additions to property and equipment | (28,456) | (15,665) | ||||
Acquisitions, net of cash acquired | (169,707) | (101,184) | ||||
Distributions from (Investments in) Wilson Wolf | 2,149 | — | ||||
Proceeds from sale of Eminence | — | 17,824 | ||||
Net cash provided by (used in) investing activities | (177,781) | (19,797) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||
Cash dividends | (25,213) | (25,106) | ||||
Proceeds from stock option exercises | 19,670 | 16,977 | ||||
Long-term debt activity, net | 97,000 | (56,000) | ||||
Re-purchases of common stock | (80,042) | (19,562) | ||||
Taxes paid on RSUs and net share settlements | (21,302) | (17,853) | ||||
Other financing activity | — | (2,457) | ||||
Net cash provided by (used in) financing activities | (9,887) | (104,001) | ||||
Effect of exchange rate changes on cash and cash equivalents | (5,270) | (4,552) | ||||
Net increase (decrease) in cash and cash equivalents | (50,439) | (7,885) | ||||
Cash and cash equivalents at beginning of period | 180,571 | 172,567 | ||||
Cash and cash equivalents at end of period | $ | 130,132 | $ | 164,682 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-second-quarter-fiscal-2024-results-302050307.html
SOURCE Bio-Techne Corporation
FAQ
What was Bio-Techne's organic revenue for the second quarter?
What was the GAAP EPS for the second quarter?
Who was appointed as President of the Diagnostics and Genomics segment?
What were the second quarter net sales for the Protein Sciences segment?
What was the impact of the Lunaphore acquisition on the Diagnostics and Genomics segment's operating margin?
